Name: David Baker BSc, PhD
Affiliation: Neuroimmunology Unit, Blizard Institute
Barts and the London School of Medicine and Dentistry
Queen Mary University of London
Although his interests have varied over time, his focus has been on control of neuroimmunological disease and its translational relevance to multiple sclerosis (MS). He has published over 200 peer-reviewed papers.
His early career focused on genetics; T cell biology, neuroimmunology and blood brain barrier and his group uncovered the first experimental evidence for symptomatic benefit of cannabis and cannabinoids in the control of spasticity. This work led to the development of cannabis-based licensed medicines for treatment of spasticity in MS. His research has focussed development of agents to treat symptoms and promote neuroprotection. He founded a University spin-out company in 2005 to develop his intellectual property and has moved a treatment from Invention to human studies and actively works with a medicinal chemist involved in drug discovery. He teamed up with the Professor Gavin Giovannoni to lead the pre-clinical part of a translational neuroscience team and has generated a number of models to mimic aspects of multiple sclerosis to facilitate translation of ideas from bench to bedside. The team have also embraced public engagement of science to run a MS research blog (www.ms-res.org).